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Objective: To explore the dose equivalence ratio and treatment 
costs for abobotulinumtoxinA and incobotulinumtoxinA 
for patients with focal dystonias.
Design: Patient chart review.
Subjects/Patients: Adult patients with blepharospasm 
(n = 19), cervical dystonia (n = 122), hemifacial spasm (n = 91) 
or segmental/generalized dystonia (n = 19) at a neurology 
outpatient clinic.
Methods: Patients were switched from established abobo-
tulinumtoxinA therapy to incobotulinumtoxinA at a ~4:1 
unit ratio. Dose requirements, injection intervals, treatment 
efficacy, and adverse events were evaluated for a period of 
≥ 1 year.
Results: Patients were switched from abobotulinumtoxinA to 
incobotulinumtoxinA with a mean dose ratio of 4.07 (stand-
ard deviation (SD) 0.50). After switching, incobotulinum-
toxinA dose requirements remained stable; the mean (SD) 
dose ratio at the end of the review period (52–219 weeks 
after switching) was 3.89 (SD 0.58). Injection intervals also 
remained stable after switching. Adverse events were injec-
tion site pain (n = 45) and bruising (n = 4). Five patients (2.0%) 
discontinued incobotulinumtoxinA treatment: 4 stopped 
receiving injections, and 1 reverted to abobotulinumtoxinA. 
Switching to incobotulinumtoxinA reduced the mean toxin 
expenditure to 76.7% of the cost of abobotulinumtoxinA.
Conclusion: For patients with conditions commonly treated 
in dystonia clinics, switching from abobotulinumtoxinA to 
incobotulinumtoxinA, given at equivalent doses (~4:1 unit 
ratio) at similar intervals, was effective, well tolerated and 
achieved cost savings.
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IntROductIOn
Intramuscular injections of botulinum toxin are the first-
line treatment for most types of focal dystonia, including 
blepharospasm, hemifacial spasm and cervical dystonia (cd) 
(1). three botulinum toxin type A products are currently avail-
able in Europe and the uSA: abobotulinumtoxinA (dysport®, 
Ipsen), incobotulinumtoxinA (Xeomin®, Merz Pharmaceuti-
cals) and onabotulinumtoxinA (Botox®, Allergan). All products 
contain neurotoxin type A, derived from the Hall strain of 
Clostridium botulinum, but differ in their exact molecular 
composition and excipients (2). In abobotulinumtoxinA and 
onabotulinumtoxinA, the active 150 kda neurotoxin is part of 
a larger complex with other proteins, which are not thought to 
affect the biological activity, diffusion profile or stability of 
the neurotoxin (3). IncobotulinumtoxinA contains the purified 
neurotoxin without complexing proteins (2).
the availability of several botulinum toxin type A products 
raises the opportunity to explore conversion between agents. 
the potency of all botulinum toxin type A formulations is meas-
ured in units based on the median lethal intraperitoneal dose 
in mice, but methodological details of potency assays differ 
between manufacturers. Hence, unit labelling is specific to 
each formulation and universal unit conversion factors between 
formulations do not exist. In controlled clinical trials, abobo-
tulinumtoxinA and onabotulinumtoxinA have been reported 
to have similar efficacy and tolerability when used at a 4:1 
unit ratio in treating blepharospasm or hemifacial spasm (4) 
and at a 3:1 unit ratio in cd (5). In retrospective studies, dose 
equivalence ratios between 1.7:1 and 6:1 have been described 
(6–8). IncobotulinumtoxinA and onabotulinumtoxinA have 
shown therapeutic equivalence in treating blepharospasm and 
cd at a 1:1 unit ratio in controlled clinical studies (reviewed 
in 9). controlled comparison studies of incobotulinumtoxinA 
and abobotulinumtoxinA have not been published.
We have reviewed data from patients with focal dystonias 
in our neurology outpatient clinic who were switched from 
established therapy with abobotulinumtoxinA to incobotuli-
numtoxinA.
MEtHOdS
Patients and settings
Our neurology outpatient clinic serves a regional catchment area in 
the west of Scotland with a population of 2 million, and provides 
botulinum toxin treatment to all cases of cd and hemifacial spasm, and 
most cases of blepharospasm, in that catchment area. From 2009, we 
switched patients from established abobotulinumtoxinA treatment to 
incobotulinumtoxinA. In the current study, we retrospectively reviewed 
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patient chart data to evaluate a potential impact of switching on dose 
requirements, treatment intervals and treatment cost for patients with a 
follow-up period of at least one year after switching. Treatments were 
administered in our clinic by 4 experienced injectors.
Switching from abobotulinumtoxinA to incobotulinumtoxinA
Switching was generally initiated at a 4:1 unit ratio of abobotulinum-
toxinA to incobotulinumtoxinA. Following the standard procedure in 
our clinic and in accordance with the prescribing information, 500 unit 
vials of abobotulinumtoxinA were reconstituted to a final volume of 
2.5 ml and 100 unit vials of incobotulinumtoxinA to 2.0 ml. therefore, 
switching at a 4:1 unit ratio did not affect the injection volume.
Injection intervals
the standard initial treatment interval for botulinum toxin injections at 
our clinic is 13 weeks. Appointments for the next injection were made 
at each injection visit; however, intervals were reviewed at each visit 
and increased or decreased according to clinical need. Adjustments 
were made stepwise, usually in 1-week steps. The minimum injection 
interval at our clinic is 10 weeks.
Assessments
At each clinic visit, the effects of the previous botulinum toxin treat-
ment were captured using a standard assessment form. treatment 
efficacy was recorded as described by patients on a 7-point scale: 
excellent, very good, good, fairly good, fair, poor, or negligible. the 
duration of treatment effect during the previous treatment cycle was 
rated by patients on a 4-point scale as: excellent duration, good dura-
tion, a few weeks or short-lived, where a few weeks was defined as 
approximately 5 weeks. Patients were encouraged to report any adverse 
events (AEs) and actively questioned about any occurrences of swal-
lowing difficulties, bruising at the injection site, dry eye, eyelid ptosis, 
facial weakness and diplopia, which were graded as mild, moderate or 
severe, as reported by patients. Based on these assessments, botulinum 
toxin doses, injection sites and injection interval for the next treatment 
were adjusted to patients’ clinical needs.
RESuLtS
Patients
Botulinum toxin treatment was switched in 257 patients with 
blepharospasm, cd, hemifacial spasm, or segmental or gener-
alized dystonia. Of these, 251 (97.7%) received incobotulinum-
toxinA for one year or longer and were included in this analysis. 
the most commonly treated disorders were cd and hemifacial 
spasm. Further patient characteristics are summarized in table I. 
Six patients stopped receiving incobotulinumtoxinA within 
one year of switching. Of these, 3 patients stopped treatments 
because their symptoms settled, 1 patient with hemifacial 
spasm stopped when going for surgery, 1 patient stopped as 
they felt the treatment was not working and 1 patient was lost 
to follow-up. 
The mean follow-up period after switching was 91 weeks 
(standard deviation (Sd) 31; range 52–219 weeks). during this 
period, patients received a mean of 8.3 (Sd 1.8) incobotuli-
numtoxinA treatment cycles. Five patients stopped receiving 
incobotulinumtoxinA injections more than 52 weeks after the 
switch. Of these, 4 patients stopped because they felt they did 
not benefit from receiving any botulinum toxin treatment. One 
patient reverted to abobotulinumtoxinA due to a perceived lack 
of efficacy and preference for abobotulinumtoxinA.
Dose requirements
the mean abobotulinumtoxinA dose patients received one year 
before switching was 229 units (Sd 207). At the treatment just 
prior to switching, the mean dose was 243 units (Sd 220). 
doses for patients with different conditions are summarized 
in Table I. At the first incobotulinumtoxinA treatment, the 
mean dose administered was 60.6 units (Sd 54.8). the mean 
switch dose ratio of abobotulinumtoxinA units to incobotuli-
numtoxinA units was 4.07 (Sd 0.50). 
Overall, dose requirements were stable over time; one year af-
ter switching the mean incobotulinumtoxinA dose was 62.5 units 
(SD 55.8). Follow-up data over a longer period of more than 
one year were available for 119 patients, with a mean dose 
requirement of 64.8 units (Sd 59.6) of incobotulinumtoxinA at 
the end of year 2. the mean dose ratio at the end of the review 
period (52–219 weeks after switching) was 3.89 (Sd 0.58). 
dose requirements varied for the conditions treated in our 
clinic; requirements according to diagnosis are shown in Fig. 1.
Injection intervals
Prior to switching, abobotulinumtoxinA injection intervals 
were relatively stable over time. For all patients, the mean abo-
botulinumtoxinA injection interval one year before switching 
was 12.9 weeks (Sd 2.7) and the interval directly before 
switching was 13.0 weeks (Sd 3.0). After switching to inco-
botulinumtoxinA, injection intervals remained stable during 
the follow-up period; the last mean incobotulinumtoxinA treat-
ment interval for all patients at the end of their follow-up period 
(52–219 weeks after switching) was 12.9 weeks (Sd 3.3). 
Overall, mean injection intervals were similar for patients 
with different diagnoses. Injection intervals before and after 
switching according to diagnosis are shown in Fig. 2. 
table I. Patient characteristics and abobotulinumtoxinA dosing before switching (n = 251)
diagnosis
Patients
n (%)
Age, years
Mean (Sd)
Female gender 
%
AbobotulinumtoxinA dose, units
1 year pre-switch
Mean (Sd)
Last pre-switch
Mean (Sd)
Blepharospasm 19 (7.6) 63.4 (12.0) 47.4 80 (30) 79 (26)
cervical dystonia 122 (48.6) 57.2 (13.7) 73.8 379 (166) 402 (171)
Hemifacial spasm 91 (36.3) 62.5 (12.6) 73.3 46 (38) 47 (43)
Segmental or generalized dystonia 19 (7.6) 55.4 (14.7) 73.7 288 (227) 326 (246)
Sd: standard deviation.
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Patient-rated efficacy and duration of treatment effect
The majority of patients (84.1%) rated the efficacy of their 
incobotulinumtoxinA injections as excellent or very good 
(excellent, n = 10; very good, n = 201; good, n = 29; fairly good, 
n = 11). No patients reported efficacy ratings of fair or less. 
the duration of treatment effect was comparable for 
abobotulinumtoxinA and incobotulinumtoxinA injections. the 
majority of patients (93.6%) rated the duration of incobotu-
linumtoxinA treatment effect as excellent or good (excellent 
duration, n = 8; good duration, n = 227; a few weeks, n = 14; 
short-lived, n = 2). 
Tolerability
IncobotulinumtoxinA injections were generally well tolerated. 
throughout the observation period, and over a mean of 8.3 
incobotulinumtoxinA injection cycles, 45 patients reported pain 
at the injection site (mild, n = 4; moderate, n = 34; severe, n = 7) 
and 4 patients experienced bruising (mild, n = 3; moderate, n = 1). 
Expenditure
In our clinic, based on the mean expenditure for abobotuli-
numtoxinA per patient per year before the switch and the mean 
expenditure for incobotulinumtoxinA per patient per year after 
the switch, switching from abobotulinumtoxinA to incobotu-
linumtoxinA resulted in a mean reduction in the expenditure 
for botulinum toxin per patient per year to 76.7% (Sd 14.8) 
of the cost before switching. 
dIScuSSIOn
In our neurology outpatient clinic, patients with focal dysto-
nias who received established abobotulinumtoxinA therapy 
were switched to incobotulinumtoxinA. We retrospectively 
reviewed the charts of patients who received incobotulinum-
toxinA for at least one year after switching and found that 
a conversion at a ~4:1 unit ratio of abobotulinumtoxinA to 
incobotulinumtoxinA resulted in similar treatment effects in 
terms of efficacy, duration of treatment benefit and adverse 
events profile. Importantly, after switching at a 4:1 unit ratio, 
the overall incobotulinumtoxinA dose requirements and injec-
tion intervals remained stable at subsequent treatments over the 
observation period (52–219 weeks). the largest variations in 
dose requirements were seen for blepharospasm and segmen-
tal or generalized dystonia. However, few patients with these 
conditions were included in this analysis.
To our knowledge, this is the first report describing a switch 
from treatment with abobotulinumtoxinA to incobotulinum-
toxinA in daily neurological practice; controlled head-to-head 
clinical trials comparing these botulinum toxin formulations in 
patients with neurological conditions have not been reported. 
IncobotulinumtoxinA has shown therapeutic equivalence to 
onabotulinumtoxinA in controlled clinical studies (9); hence, 
it would be expected that the clinical conversion ratio be-
tween abobotulinumtoxinA and incobotulinumtoxinA would 
be similar to the conversion ratio between abobotulinum-
toxinA and onabotulinumtoxinA. Previous clinical studies and 
retrospective reviews have described abobotulinumtoxinA to 
onabotulinumtoxinA conversion ratios ranging from ~1.7:1 to 
6:1 (4–8), in agreement with our findings.
Botulinum toxin doses used in our clinic are within the 
recommended dose range for each indication according to 
product prescribing information, but lower than doses used 
in controlled abobotulinumtoxinA and incobotulinumtoxinA 
clinical trials (10–13), and those described in many clinical 
practice reports (6, 7, 14). However, treatment approaches 
vary between different countries and clinics and will evolve 
over time. For instance, our treatment approach for hemi-
Fig. 1. IncobotulinumtoxinA dose requirements by diagnosis over time. 
Sd: standard deviation; cd: cervical dystonia; HFS: hemifacial spasm.
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facial spasm was refined during the review period from 
injecting botulinum toxin into 3 sites to distributing the same 
total dose across 5 sites. Importantly, botulinum toxin doses 
received were regularly reviewed, individualized and adjusted 
throughout the review period based on efficacy and duration 
of treatment effect to optimize effectiveness, suggesting that 
dosing was appropriate for the patient population in our clinic.
Overall, incobotulinumtoxinA treatment was generally well 
tolerated. the only AEs reported by patients (pain and bruising) 
were restricted to the area around the injection site and were 
consistent with AEs expected from any injection procedure. 
Other AEs that have been observed in clinical trials of botu-
linum toxin treatment for focal dystonias (reviewed in (14)) 
were not reported, despite active questioning regarding the 
occurrence of swallowing difficulties, dry eye, eyelid ptosis, 
facial weakness or diplopia at each clinic visit. As the incidence 
of AEs after botulinum toxin injections has been reported to be 
dose-related (10, 14), this may in part reflect the lower doses 
used in our clinic compared with many clinical trials.
the number of patients who stopped receiving incobotu-
linumtoxinA injections 12 months post switching was low 
(2.0%, 5/251), and 4 of the 5 patients who stopped inco-
botulinumtoxinA injections stopped receiving any botulinum 
toxin treatment. Importantly, we did not observe a difference 
in the number of patients who stopped receiving botulinum 
toxin injections during treatment with abobotulinumtoxinA 
or incobotulinumtoxinA.
We found that, in our clinic, switching from abobotulinum-
toxinA to incobotulinumtoxinA reduced the expenditure on 
botulinum toxin per patient per year to a mean 76.7% of the 
pre-switch cost. This is a substantial cost saving, since previous 
phamacoeconomic evaluations of botulinum toxin therapy for 
focal dystonias have shown that the overall treatment costs are 
largely made up of the cost of the toxin itself (15). Of note, 
the expenditure is based on the actual dose of botulinum toxin 
administered.
Potential limitations of this study are the retrospective nature 
of the analysis and the reliance on patient-reported outcomes 
to assess efficacy and treatment duration. However, reliance 
on patient-reported information is typical of routine clinical 
practice. the main strengths are the large number of patients, 
who were treated by 4 experienced injectors throughout the 
review period, and the low rate of treatment discontinuation.
In conclusion, switching from abobotulinumtoxinA to inco-
botulinumtoxinA at a 4:1 unit ratio resulted in good therapeutic 
effectiveness in terms of treatment efficacy, duration of treat-
ment effect and adverse events profile, and reduced treatment 
costs for patients with a range of conditions commonly treated 
in our dystonia clinic.
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